New hope for kids with deadly brain cancer: targeted drug trial launches
NCT ID NCT07206849
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time
Summary
This study tests a drug called tovorafenib in children and young adults (ages 1 to 39) newly diagnosed with aggressive brain tumors (high-grade glioma or DIPG) that have specific genetic changes. The goal is to see if the drug can help them live longer. About 79 participants will receive tovorafenib after radiation therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE INTRINSIC PONTINE GLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can trained immune cells outsmart brain tumors?
- Could cutting a wider margin around brain tumors extend survival?
- Can a Tumor's genetic blueprint guide better treatment for kids with brain cancer?
- Can a 7-Week brain tumor treatment beat the standard 10-Week plan?
- Could a parasite drug fight childhood brain tumors?
- Could an antiparasitic drug boost radiation against childhood brain tumors?